Difference between revisions of "Tivozanib (Fotivda)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "https://ascopubs.org/doi/full/10.1200" to "https://doi.org/10.1200")
m
Line 2: Line 2:
 
From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=561728 NCI Drug Dictionary]: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.
 
From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=561728 NCI Drug Dictionary]: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.
  
−
=Preliminary data=
+
=Diseases for which it is used=
 +
*[[Renal cell carcinoma]]
  
−
==[[Renal cell carcinoma]]==
+
==History of changes in FDA approval==
−
# '''AV-951-09-902:''' Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, Tomczak P, Lyulko O, Alyasova A, Harza M, Kogan M, Alekseev BY, Sternberg CN, Szczylik C, Cella D, Ivanescu C, Krivoshik A, Strahs A, Esteves B, Berkenblit A, Hutson TE. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013 Oct 20;31(30):3791-9. Epub 2013 Sep 9. [https://doi.org/10.1200/JCO.2012.47.4940 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569677/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24019545 PubMed]
+
''Not currently FDA approved for any indication.''
−
# '''TIVO-3:''' Rini BI, Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, Verzoni E, Needle MN, McDermott DF. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2019 Dec 3. [Epub ahead of print] [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30735-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/31810797 PubMed]
 
  
 
==Also known as==
 
==Also known as==
 
*'''Code name:''' AV-951
 
*'''Code name:''' AV-951
 +
*'''Brand name:''' Fotivda
  
 
[[Category:Drugs]]
 
[[Category:Drugs]]
 
[[Category:Oral medications]]
 
[[Category:Oral medications]]
−
[[Category:Investigational drugs]]
 
  
 
[[Category:VEGFR inhibitors]]
 
[[Category:VEGFR inhibitors]]
 +
 +
[[Category:Renal cell carcinoma medications]]
 +
 +
[[Category:EMA approved drugs]]

Revision as of 00:47, 17 February 2021

Mechanism of action

From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.

Diseases for which it is used

History of changes in FDA approval

Not currently FDA approved for any indication.

Also known as

  • Code name: AV-951
  • Brand name: Fotivda
Retrieved from "https://hemonc.org/w/index.php?title=Tivozanib_(Fotivda)&oldid=47144"